GlassScriptPhysician profile
Gurinder P Narain
NPI 1265400410
$2,752.78
in general payments reported to CMS, 2019-2025
24 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $416 · 2021: $327 · 2022: $258 · 2023: $382 · 2024: $512 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,250.48 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $251.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $243.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $127.63 | 2020-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $108.58 | 2022 | |
| Abbvie INC. | $100.01 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $99.56 | 2025 | Tarpeyo |
| Amgen INC. | $66.33 | 2020-2023 | Evenity, Prolia, Repatha |
| Mannkind Corporation | $62.53 | 2019-2020 | |
| Eisai INC. | $61.36 | 2021 | |
| Ironwood Pharmaceuticals, INC | $51.70 | 2023 | Linzess |
| Ascensia Diabetes Care US INC. | $41.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.55 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.34 | 2021 | |
| Abbott Laboratories | $33.64 | 2021-2025 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.18 | 2020 | |
| Nevro Corp. | $24.10 | 2023 | Senza |
| Seqirus USA INC | $22.85 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $21.06 | 2025 | Voquezna |
| Novo Nordisk INC | $20.33 | 2019 | |
| Metacel Pharmaceuticals LLC | $18.18 | 2022 | |
| Amarin Pharma, INC. | $17.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurinder Narain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.